-+ 0.00%
-+ 0.00%
-+ 0.00%

NextCure posts corporate presentation highlighting SIM0505 CDH6-targeting ADC program in cancer

PUBT·06/01/2026 12:18:58
Listen to the news
NextCure posts corporate presentation highlighting SIM0505 CDH6-targeting ADC program in cancer
  • NextCure highlighted SIM0505, a CDH6-targeted TOPOi antibody-drug conjugate, as its lead program advancing toward a pivotal study.
  • Phase 1 data showed 55% ORR in gynecologic cancers at therapeutic doses; dose escalation completed; dose optimization initiated.
  • Dose-optimization plan targets 5.6, 6.4, 7.2 mg/kg in PROC and uterine serous carcinoma, enrolling up to 120 patients.
  • Pivotal trial planning outlined for PROC, comparing SIM0505 with treatment of physician’s choice; n=215, expandable to 430; endpoints ORR, PFS.
  • Development strategy includes combining US and China data, expanding sites across North America and Europe, initiating CDMO tech transfer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextCure Inc. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.